Current trader consensus assigns just a 7-8% chance of a new WHO-designated COVID variant of concern emerging before 2027, driven by the absence of any SARS-CoV-2 lineages meeting VOC criteria for meaningfully higher transmissibility, severity, or immune escape as of mid-2026. ECDC and WHO tracking list only variants of interest or under monitoring, such as certain Omicron sublineages including BA.2.86 and XFG, which show limited prevalence and no major effects on hospitalizations. Ongoing genomic surveillance reveals steady circulation of existing strains without the rapid, high-impact shifts seen in earlier pandemic waves, while widespread immunity from prior infections and updated vaccines continues to limit severe outcomes. With roughly five months remaining, the lack of fresh signals of concern reinforces the strong probability assigned to no new designation.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$243,750 Vol.
$243,750 Vol.
Oui
$243,750 Vol.
$243,750 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Current trader consensus assigns just a 7-8% chance of a new WHO-designated COVID variant of concern emerging before 2027, driven by the absence of any SARS-CoV-2 lineages meeting VOC criteria for meaningfully higher transmissibility, severity, or immune escape as of mid-2026. ECDC and WHO tracking list only variants of interest or under monitoring, such as certain Omicron sublineages including BA.2.86 and XFG, which show limited prevalence and no major effects on hospitalizations. Ongoing genomic surveillance reveals steady circulation of existing strains without the rapid, high-impact shifts seen in earlier pandemic waves, while widespread immunity from prior infections and updated vaccines continues to limit severe outcomes. With roughly five months remaining, the lack of fresh signals of concern reinforces the strong probability assigned to no new designation.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour



Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes